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Abstract
Parkinson’s disease (PD) is the second most common neurodegenerative 
disorder and manifests as bradykinesia, rigidity, resting tremor and posture 
instability. Although the disease symptomatology can be well controlled by 
levodopa, related medications and deep brain stimulation, the etiology of 
PD remains obscure. The epidemiological features have been discussed in 
depth in the literature, but the methodologies used to approach the issues 
have varied greatly, and the results cover a wide range of factors and are 
generally inconclusive. The crude prevalence rate of PD has been reported 
to range from 15 per 100,000 to 12,500 per 100,000, and the incidence of 
PD from 15 per 100,000 to 328 per 100,000, with the disease being less 
common in Asian countries. Risk factor studies have pinpointed cigarette 
smoking, coffee/tea consumption and alcohol drinking as being mostly 
related to a lower risk of PD. The relationship between a higher risk of PD 
and drinking well-water and being exposed to herbicides/pesticides is 
controversial. Systemic diseases including gout, hyperlipidemia and hyper-
tension may be related to a reduced risk of PD. A family history of PD, 
tremor, depression and head injury are related to a higher risk of PD. 
Genetic studies of the glucocerebrosidase, parkin and LRRK2 genes have 
contributed to our understanding of familial PD but not of sporadic PD. 
The health-related quality of life of PD patients is related not only to their 
motor disability, but also to their non-motor symptoms of depression, 
sleep disturbance, bladder and sexual dysfunction. The economic burden 
of PD is enormous, and the annual cost of medical service per PD patient 
can reach c13,804 (NT$599,547). [Tzu Chi Med J 2010;22(2):73–81]
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1. Introduction
Parkinson’s disease (PD) is the second most common 
neurodegenerative disease and manifests as brady-
kinesia, resting tremor, cogwheel rigidity and posture 
instability. The slowly progressive character of the dis-
ease means that development may last for 20 years. 
Although the motor symptoms of PD can be well con-
trolled by levodopa and other adjunctive medications 
in the early stages of the disease, treatment-related 
complications will inevitably occur after 5–7 years. As 
the disease progresses, the cardinal motor symptoms 
of PD as well as cognitive decline, neuropsychological 
problems, autonomic failure and treatment-related 
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complications associated with levodopa will enor-
mously reduce the patient’s activities of daily living 
(ADL) and health-related quality of life (HR-QoL) [1]. 
The World Health Organization has conducted numer-
ous projects to raise awareness of the public health 
importance of PD since 1997. One of the completed 
projects is the Global Parkinson’s Disease Survey 
(GPDS), a multinational survey across three continents 
(and including Canada, Italy, Japan, Spain, UK and 
USA), which showed that the QoL of PD patients was 
intimately associated not only with the severity of the 
disease and its treatment, but also with patients’ satis-
faction with the explanation of their diagnosis, their 
emotional state and the current level of their optimism 
about the disease. The burden and public health im-
portance of neurological diseases such as PD has been 
underestimated [2]. The task of carrying out public 
health investigations into PD needs enthusiasm to carry 
on. In this context, multidisciplinary teamwork is able 
to improve the wellbeing of PD patients. In this review, 
we will focus our attention on the current understand-
ing of the risk factors of PD, its comorbidities, the eco-
nomic burden of PD, and the HR-QoL of PD patients.
2. Prevalence and incidence
Prevalence is defined as the total number of persons 
with a disorder within a given population at a fixed 
point in time. Incidence is defined as the number of 
new cases of a disorder diagnosed during a specific 
time period [3]. The crude prevalence rate of PD in 
European countries has been found to range from 
65.6 per 100,000 to 12,500 per 100,000, and the 
incidence from 5 per 100,000 to 346 per 100,000 
[3–12]. In Asian countries, the crude prevalence rates 
seem to be lower and range from 15 per 100,000 to 
328 per 100,000 [6,13–16]. Interestingly, the wide 
ranges for the prevalence and incidence rates for PD 
from various research groups might be due to differ-
ences in their research methodologies; these include 
case finding protocols, diagnostic criteria and the age 
of the study population [5]. How ever, in this context, 
it seems likely that the ethnic difference may be at-
tributed to different environmental exposure risks or 
interethnic differences in genetic susceptibility genes.
3. Risk factors
The unknown basis of the etiology of PD makes the 
disease incurable. It is now considered to be a multi-
factorial disease resulting from both environmental ex-
posure to various factors and differences in genetic 
susceptibility. Multiple environmental factors that may 
be related to the etiology of PD include exposure to 
pesticides and herbicides, intake of various metals 
(copper, lead-copper, lead-iron, iron-copper), drinking 
well-water and exposure to a neurotoxin (1-methyl-1-4 
phenyl-1,2,3,6-tetrahydropyridine), yet none of these 
has been identified as the sole causative agent of 
PD [17–21].
Although mutations in the parkin, LRRK2, and 
glucocerebrosidase genes are commonly found in 
multiethnic populations with familial early PD, such 
mutations are rare in sporadic early PD, which 
accounts for most patients with PD [22–24]. Thus, 
environmental factors may be more important than 
ethnicity and genetic factors in the etiology of PD [25].
In contrast to the high risk factors associated with 
PD, many epidemiological studies have shown that 
cigarette smoking is inversely associated with the oc-
currence of PD [19,20,26,27], even in a population 
characterized by a high prevalence of pesticide expo-
sure [26], although pesticides or herbicides may not 
necessarily be associated with PD [19,21]. Coffee and 
tea drinking have also been suggested to be associ-
ated with a lower risk of PD [28]. Physical activities 
may also be an issue such that a higher level of activ-
ity may lower the risk of PD [29]. Also mentioned in 
one paper is the possibility that an increase in body 
mass index is positively associated with a higher risk 
of PD [30] (Tables 1–3 [19–24,26,28–38]).
4. Comorbidity
4.1. Neuropsychological events
PD as a neurodegenerative disease is characterized 
clinically by motor symptoms, which are related to 
dopamine deficiency; this occurs as a consequence 
of the degeneration of the substantia nigra pars com-
pacta and has gained much attention in terms of 
treatment intervention.
It is estimated that neurologists overlook discuss-
ing crucial non-motor symptoms of PD (including de-
pression, anxiety, fatigue, and sleep disturbance) with 
their patients more than 50% of the time; this esti-
mate comes from a prospective study of 101 patients 
[39]. However, only 12% of the sample had no non-
motor symptoms in a brief report describing 99 
non-demented PD patients [40]. Indeed, associated 
non-motor comorbidity in PD patients is a significant 
source of disability and impaired QoL. The non-motor 
symptom complex of PD includes neuropsychiatric 
symptoms, sleep disorders, dysautonomia and sen-
sory complaints [41]. These non-motor symptoms are 
usually correlated with advancing age and disease 
severity, while other non-motor symptoms such as 
olfactory dysfunction, REM sleep behavior disorder, 
depression and gastrointestinal symptoms can occur 
early in the disease and deteriorate in parallel with 
the motor symptoms [41–44].
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Neuropsychiatric and cognitive problems vary from 
anxiety, apathy and depression to dementia [45]. In 
a Sydney multicenter study of PD with prospective 
and long-term (more than 15 years) follow-up, high 
rates of PD with dementia were reported [46]. An-
other systematic review of prevalence studies of de-
mentia in PD patients suggested that 24–31% of 
patients have dementia and that 3–4% of dementia in 
the whole population is due to PD with dementia [47]. 
Multiple regression analyses in a large-scale, nation-
wide, cross-sectional, epidemiological study revealed 
that PD severity was the strongest predictor of de-
mentia risk while other neuropsychiatric syndromes 
made only modest additional contributions [48].
Depression is among the most common non-mo-
tor features of PD along with cognitive impairment 
and autonomic dysfunction [49]. The estimated prev-
alence of depression in PD patients is thought to vary 
from 10% to 45% depending on the criteria used 
[40,50,51]. Irrespective of whether a neuropatholog-
ical process or a reactive basis underlies depression 
in PD, the implication from both an epidemiological 
and neurobiological point of view is that this issue 
needs to be investigated further. Impaired cognitive 
function and the presence of thought disorders are 
significant predictors of major depression in PD pa-
tients [52]. Impairment of serotoninergic neurotrans-
mission as well as effects on limbic noradrenergic and 
dopaminergic mechanisms exist in depressed patients 
with PD [53]. The severity of depression and impaired 
cognition accounted for 37% of the variance in disa-
bility using the Unified Parkinson’s Disease Rating 
Scale ADL score [54]. Thus, these psychiatric or non-
motor symptoms contribute significantly to disability 
among PD patients over 15 years of follow-up [46].
The occurrences of anxiety, fatigue, sleep distur-
bance and sensory symptoms in PD patients were 
33%, 40%, 47% and 63%, respectively, as reported 
by Shulman et al [40]. The authors also demon-
strated that as the number of non-motor symptoms 
increased, PD severity also increased. Bladder and 
sexual dysfunction in PD patients do not respond to 
dopaminergic treatment and may influence the QoL 
of PD patients despite that fact that they remain able 
to move well [55]. Drooling is another non-motor prob-
lem that may cause significant difficulty in speaking 
(7.27% vs. 0%; p < 0.01), eating (3.64% vs. 0%; p = 
0.01) and interacting socially (12.73% vs. 0%; p < 0.01) 
as compared to PD non-droolers; this may cause a 
significant decline in QoL [56].
4.2. Systemic disease
Since PD is a neurodegenerative disease that occurs 
mostly in aged patients, it may be associated with 
other systemic diseases such as diabetes mellitus, 
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hypertension, coronary artery disease, cerebral vascu-
lar disease, spinal degenerative disease, orthopedic 
disorders and other neurodegenerative disorders. 
Ac cepting that the results are somewhat inconsistent 
due to methodological differences in the few case-
controlled studies available, the prevalence of dia-
betes mellitus, hypertension, and coronary artery 
disease are similar between PD patients and the gen-
eral population. Stroke is the exception and has a 
lower prevalence among PD patients [57]. Through 
a comprehensive understanding of the temporal re-
lation and severity of these medical diseases in as-
sociation with PD, we may be able to modulate the 
risk of PD to some degree and improve the QoL of 
patients [6] (Table 2 [20,30,36,37]).
5. Economic burden
According to the Ministry of the Interior of Taiwan, 
in the year 2009, the total population of Taiwan 
was 23.12 million, and the population aged above 
65 years was 2.457 million, which is about 10% of 
the whole population. Since the crude prevalence 
rate of PD for those aged more than 60 years is 1%, 
in the year 2009, there would have been more than 
20,000 persons who might have been affected by PD. 
PD is a slowly progressive disease, and the therapeu-
tic period may last for more than 20 years. Treatment 
modalities become more complicated as the disease 
progresses and the direct costs of treatment will also 
increase significantly in proportion to the increase in 
Hoehn and Yahr stage [58]. A combination of differ-
ent medical regimens, such as levodopa, dopamine 
agonists, COMT (catechol-O-methyl transferase) inhib-
itors, MAO (monoamine oxidase) inhibitors, amanta-
dine and anticholinergics will be prescribed when 
the patient starts to experience symptoms of wear-
ing off, on-off phenomenon, and treatment-related 
dyskinesia [59]. Although medications play a major 
role throughout all stages of the disease, the direct 
and indirect costs of the disease are enormous and 
it is inevitable that motor fluctuation, dyskinesia and 
neuropsychological problems will occur, which will 
result in the patient’s QoL deteriorating [58,60–63]. 
In this situation, it is no wonder that more invasive 
interventions such as the apomorphine pump, con-
tinuous intestinal delivery of levodopa through a 
pumping device (DuoDopa; Solvay Pharmaceuticals 
GmbH, Rostock, Germany) and/or deep brain stimu-
lation are needed as adjunct procedures to improve 
the patient’s ADL [17]. To compare the different treat-
ment modalities in terms of efficacy in order to ob-
tain the PD patient’s direct and indirect costs is thus 
very important [64,65].
Despite the high direct medical cost of PD noted 
in the literature, in Europe it has been found that the 
direct costs of the economic burden of PD are largely 
attributable to inhospital care and nursing home 
costs, and the cost of medications contributes only a 
small percentage to the total costs [58]. So, it is no 
wonder that Roland et al stated in their recent study 
that caregivers experience a far greater burden from 
the “mental stress” than from the “physical stress” due 
to the fact that they need to be continuously vigilant 
and tend to worry constantly about their spouse’s 
safety, which to them is priceless [66]. From a thor-
ough understanding of PD patients’ distribution in 
society and their treatment course during hospital 
care, it should be possible for medical administra-
tions to allocate health care costs in a more efficient 
way and slow the accelerating economic burden of 
PD (Table 4 [58,60–63]).
6. Health-related quality of life
Factors affecting the HR-QoL of PD patients include 
the following: treatment-related neurobehavioral 
changes, non-motor symptoms, motor complications, 
education, and surgical intervention. The motor symp-
toms are obvious and easy to detect, and the related 
research articles are straightforward and widely un-
derstood. In contrast, the underestimated non-motor 
symptoms, such as depression, are claimed to be the 
most important predictive factors of QoL among PD 
patients [67]. The ability to communicate and be mo-
bile, as well as the associated HR-QoL of PD patients, 
can be improved through self-managed rehabilitation, 
which is positively related to rehabilitation hours [68]. 
In addition to the clinical setting, the direct and indi-
rect economic burden of the disease are negatively 
associated with the QoL of both the PD patient and 
their caregiver [60]. Social support plays a more 
important role in the HR-QoL of PD patients com-
pared to clinical parameters. This is especially true 
in Eastern countries, such as Russia. This result was 
demonstrated by the work of Winter et al, who con-
cluded that social service support for patients with 
PD should be considered during the development of 
national health care programs in order to improve the 
HR-QoL of PD patients [69]. However, knowledge of 
the factors affecting the HR-QoL of PD patients and 
associated research remain quite limited [1]. There-
fore, treatment strategies capable of improving QoL in 
PD in the future will rely on the identification of the 
factors that most influence the QoL of PD patients 
using large population-based studies of PD patients.
7. Conclusion
PD patients increase in number with age and are 
more prevalent in the aging populations of developed 
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countries. Several susceptible genes have been iden-
tified but these genetic factors are only important 
in a small number of patients. Among a variety of 
environmental factors, smoking seems to be the 
most important and is an inversely correlated risk 
factor for PD. The limited methodologies used and 
underrepresented comorbidities that accompany PD 
hamper the possibility of improving PD patients’ QoL 
and thus hinder the amelioration of the economic 
burden of the disease. Although there have been 
a number of studies with strict methodology and 
long patient follow-up that have been conducted in 
Europe and America, good data from Asia is lacking. 
Studies across continents are needed in order to 
fully explore various areas such as risk factors, comor-
bidities and treatment trends, as well as to investi-
gate the econo mic burden of PD. These studies are 
urgently needed in order to improve the QoL of PD 
patients.
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